Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation

 
• By Joseph Haas
  
SubQ
Genentech plans to seek approval of a subcutaneous version of Tecentriq • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D